Article: Helicon Group Limited (ASX:HCG) Secures Milestone Regulatory Approval In China For Skin Regeneration Medical Technology ReCell(R)

HELICON GROUP LIMITED (ASX:HCG) today announced that the Chinese State Food and Drug Administration (SFDA) has granted approval for the skin regeneration concept and device, ReCell(R).

KEY POINTS

- Chinese State Food and Drug Administration approves skin regeneration concept and device: ReCell(R)

- Proven product effectiveness in treatment of burns and small wounds

- Significant market demand for the product in China

- Importation issues with some components of the device to be resolved with the SFDA

Following an exhaustive approval process, due in part to the pioneering nature and complexity of the kit, the SFDA has approved the product concept and ReCell(R) kit. Importation issues with some ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!